» Articles » PMID: 38148901

Drug Transport by Red Blood Cells

Overview
Journal Front Physiol
Date 2023 Dec 27
PMID 38148901
Authors
Affiliations
Soon will be listed here.
Abstract

This review focuses on the role of human red blood cells (RBCs) as drug carriers. First, a general introduction about RBC physiology is provided, followed by the presentation of several cases in which RBCs act as natural carriers of drugs. This is due to the presence of several binding sites within the same RBCs and is regulated by the diffusion of selected compounds through the RBC membrane and by the presence of influx and efflux transporters. The balance between the influx/efflux and the affinity for these binding sites will finally affect drug partitioning. Thereafter, a brief mention of the pharmacokinetic profile of drugs with such a partitioning is given. Finally, some examples in which these natural features of human RBCs can be further exploited to engineer RBCs by the encapsulation of drugs, metabolites, or target proteins are reported. For instance, metabolic pathways can be powered by increasing key metabolites (i.e., 2,3-bisphosphoglycerate) that affect oxygen release potentially useful in transfusion medicine. On the other hand, the RBC pre-loading of recombinant immunophilins permits increasing the binding and transport of immunosuppressive drugs. In conclusion, RBCs are natural carriers for different kinds of metabolites and several drugs. However, they can be opportunely further modified to optimize and improve their ability to perform as drug vehicles.

Citing Articles

A Microfluidic Approach for Intracellular Delivery into Red Blood Cells: A Deeper Understanding of the Role of Chemical/Rheological Properties of the Cellular Suspension.

Bernardelli C, Piergiovanni M, Bianchi E, Carlo-Stella C, Costantino M, Casagrande G Ann Biomed Eng. 2025; .

PMID: 39971860 DOI: 10.1007/s10439-025-03678-2.


An outer membrane vesicle specific lipoprotein promotes aggregation on red blood cells.

Rothenberger C, Yu M, Kim H, Cheung Y, Chang Y, Davey M Curr Res Microb Sci. 2024; 7:100249.

PMID: 38974668 PMC: 11225709. DOI: 10.1016/j.crmicr.2024.100249.


Efficient and highly reproducible production of red blood cell-derived extracellular vesicle mimetics for the loading and delivery of RNA molecules.

Biagiotti S, Canonico B, Tiboni M, Abbas F, Perla E, Montanari M Sci Rep. 2024; 14(1):14610.

PMID: 38918594 PMC: 11199497. DOI: 10.1038/s41598-024-65623-y.


Back to the Basics of SARS-CoV-2 Biochemistry: Microvascular Occlusive Glycan Bindings Govern Its Morbidities and Inform Therapeutic Responses.

Scheim D, Parry P, Rabbolini D, Aldous C, Yagisawa M, Clancy R Viruses. 2024; 16(4).

PMID: 38675987 PMC: 11054389. DOI: 10.3390/v16040647.


Towards clinical adherence monitoring of oral endocrine breast cancer therapies by LC-HRMS-method development, validation, comparison of four sample matrices, and proof of concept.

Jacobs C, Radosa J, Wagmann L, Zimmermann J, Kaya A, Aygun A Anal Bioanal Chem. 2024; 416(12):2969-2981.

PMID: 38488952 PMC: 11045636. DOI: 10.1007/s00216-024-05244-6.

References
1.
Zaitsev S, Danielyan K, Murciano J, Ganguly K, Krasik T, Taylor R . Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis. Blood. 2006; 108(6):1895-902. PMC: 1895545. DOI: 10.1182/blood-2005-11-012336. View

2.
Ataullakhanov F, Batasheva T, VITVITSKII V . [Effect of temperature, daunorubicin concentration and suspension hematocrit on daunorubicin binding by human erythrocytes]. Antibiot Khimioter. 1994; 39(9-10):26-9. View

3.
Manchester K, Waters L, Haider S, Maskell P . The blood-to-plasma ratio and predicted GABA-binding affinity of designer benzodiazepines. Forensic Toxicol. 2022; 40(2):349-356. PMC: 9715504. DOI: 10.1007/s11419-022-00616-y. View

4.
Mika A, Stepnowski P . Current methods of the analysis of immunosuppressive agents in clinical materials: A review. J Pharm Biomed Anal. 2016; 127:207-31. DOI: 10.1016/j.jpba.2016.01.059. View

5.
Jones A, Patel R, Marques M, Donnelly J, Griffin R, Pittet J . Older Blood Is Associated With Increased Mortality and Adverse Events in Massively Transfused Trauma Patients: Secondary Analysis of the PROPPR Trial. Ann Emerg Med. 2018; 73(6):650-661. PMC: 6517091. DOI: 10.1016/j.annemergmed.2018.09.033. View